Rheumatoid Arthritis

SAN DIEGO — Managing systemic inflammation is critical to reducing cardiovascular and pulmonary outcomes in patients with rheumatoid arthritis, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

SAN DIEGO — Although a flood of COVID-19 and long COVID research continues to emerge, concerns may be limited for rheumatologists, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

SAN DIEGO — Rheumatoid arthritis has received less attention than other diseases in recent years, but some “new concepts” may rouse it from its current “doldrums,” said a speaker at the 2024 Congress of Clinical Rheumatology West.

SAN DIEGO — New imaging technologies, and improved use of the ones currently available, may move rheumatology closer to precision medicine in inflammatory arthritis, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

Rates of osteoporosis and osteoporotic fractures have fallen significantly among patients with rheumatoid arthritis over the past 24 years, according to a single-center study published in RMD Open.

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

The implementation of treat-to-target approaches for rheumatoid arthritis remains largely suboptimal, but could be improved with telehealth and other measures, according to data published in Arthritis Care & Research.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.